Skip to content

Study · Animal study (in vivo) · mouse · 2002

17 results

[Effect of Epitalon and Vilon treatment on mammary carcinogenesis in transgenic erbB-2/NEU mice].

Alimova IN, Bashurin DA, Popovich IG, Zabezhinskiĭ MA, Volkov MA, Provinciali M, Franceschi C, Khavincon BKh, Anisimov VN

Voprosy onkologii1 Jan 2002

PMID12101568 (opens in a new tab)PepBankPUB-12101568
Publisher pageAsk about this study
Jump to 17 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study17

17 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In erbB-2/neu transgenic mice, mammary tumor induction did not differ between the control and treated groups until age 9 months.

    In plain wordsIn mice, tumor induction did not differ between treated and control groups up to 9 months of age.

    Peptide
    Epitalon
    Outcome
    No significant changeTumor induction until age 9 months
    Study

    mousen: not reported in source

    transgenic erbB-2/neu FVB mice with mammary carcinogenesis
    Comparator
    Saline control
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1 meg · subcutaneous · 5 days in succession once a month from age 2 monthsAs given in this study (mouse).

    Source sentences

    Summary
    The characteristics of mammary tumor induction in the control and experimental groups did not differ until the age of 9 months.
    1 context sentence
    Summary · context
    Female transgenic FVB mice transfected with the mammary erbB-2/neu oncogene were injected 0.1 ml 0.9% solution of sodium chloride (control), 1 meg Vilon peptide (Lys-Glu) or Epitalon peptide (Ala-Glu-Asp-Glu), s.c., 5 days in succession once a month, beginning from the age of 2 months.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In erbB-2/neu transgenic mice, epitalon treatment inhibited mammary carcinogenesis after age 9 months.

    In plain wordsIn mice, epitalon slowed the development of breast tumors in later life.

    Peptide
    Epitalon
    Outcome
    DecreaseMammary carcinogenesis after age 9 months
    Study

    mousen: not reported in source

    transgenic erbB-2/neu FVB mice with mammary carcinogenesis
    Comparator
    Saline control
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1 meg · subcutaneous · 5 days in succession once a month from age 2 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Later on, Epitalon-treated mice revealed distinct inhibition of carcinogenesis.
    1 context sentence
    Summary · context
    Female transgenic FVB mice transfected with the mammary erbB-2/neu oncogene were injected 0.1 ml 0.9% solution of sodium chloride (control), 1 meg Vilon peptide (Lys-Glu) or Epitalon peptide (Ala-Glu-Asp-Glu), s.c., 5 days in succession once a month, beginning from the age of 2 months.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In erbB-2/neu transgenic mice, one tumor per animal was found in 16% with epitalon versus 7% with saline (p < 0.05).

    In plain wordsIn mice, more epitalon-treated animals than controls had only one tumor, which went with fewer animals having several tumors.

    Peptide
    Epitalon
    Outcome
    IncreaseMice with one tumor per animal
    Study

    mousen: not reported in source

    transgenic erbB-2/neu FVB mice with mammary carcinogenesis
    Comparator
    Saline control
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1 meg · subcutaneous · 5 days in succession once a month from age 2 monthsAs given in this study (mouse).

    Measurements

    Animals with one tumor
    16%
    Epitalon
    Animals with one tumor
    7%
    control

    Source sentences

    Summary
    One tumor per animal was detected in 7% (control), 4% (Vilon) and 16% (Epitalon) (p < 0.05).
    1 context sentence
    Summary · context
    Female transgenic FVB mice transfected with the mammary erbB-2/neu oncogene were injected 0.1 ml 0.9% solution of sodium chloride (control), 1 meg Vilon peptide (Lys-Glu) or Epitalon peptide (Ala-Glu-Asp-Glu), s.c., 5 days in succession once a month, beginning from the age of 2 months.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In erbB-2/neu transgenic mice, two or more tumors per animal were found in 56% with epitalon versus 75% with saline (p < 0.05).

    In plain wordsIn mice, fewer epitalon-treated animals than controls had two or more tumors.

    Peptide
    Epitalon
    Outcome
    DecreaseMice with two or more tumors per animal
    Study

    mousen: not reported in source

    transgenic erbB-2/neu FVB mice with mammary carcinogenesis
    Comparator
    Saline control
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1 meg · subcutaneous · 5 days in succession once a month from age 2 monthsAs given in this study (mouse).

    Measurements

    Animals with two or more tumors
    56%
    Epitalon
    Animals with two or more tumors
    75%
    control

    Source sentences

    Summary
    Two or more tumors per animal were in 75%, 95% and 56%, respectively (p < 0.05).
    1 context sentence
    Summary · context
    Female transgenic FVB mice transfected with the mammary erbB-2/neu oncogene were injected 0.1 ml 0.9% solution of sodium chloride (control), 1 meg Vilon peptide (Lys-Glu) or Epitalon peptide (Ala-Glu-Asp-Glu), s.c., 5 days in succession once a month, beginning from the age of 2 months.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In erbB-2/neu transgenic mice, the largest diameter of mammary adenocarcinoma was 33% smaller with epitalon than in controls (p < 0.05).

    In plain wordsIn mice, the largest breast tumors were smaller with epitalon than in controls.

    Peptide
    Epitalon
    Outcome
    DecreaseLargest diameter of mammary adenocarcinoma
    Study

    mousen: not reported in source

    transgenic erbB-2/neu FVB mice with mammary carcinogenesis
    Comparator
    Saline control
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1 meg · subcutaneous · 5 days in succession once a month from age 2 monthsAs given in this study (mouse).

    Measurements

    Largest tumor diameter reduction
    33%
    Epitalon vs control

    Source sentences

    Summary
    Largest diameter of mammary adenocarcinoma in the Epitalon group was smaller than in controls by 33% (p < 0.05).
    1 context sentence
    Summary · context
    Female transgenic FVB mice transfected with the mammary erbB-2/neu oncogene were injected 0.1 ml 0.9% solution of sodium chloride (control), 1 meg Vilon peptide (Lys-Glu) or Epitalon peptide (Ala-Glu-Asp-Glu), s.c., 5 days in succession once a month, beginning from the age of 2 months.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In erbB-2/neu transgenic mice, the number of mice with lung metastases was practically identical in all three groups.

    In plain wordsIn mice, the number of animals with lung metastases was practically the same with epitalon, Vilon and saline.

    Peptide
    Epitalon
    Outcome
    No significant changeMice with lung metastases
    Study

    mousen: not reported in source

    transgenic erbB-2/neu FVB mice with mammary carcinogenesis
    Comparator
    Saline control and Vilon
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1 meg · subcutaneous · 5 days in succession once a month from age 2 monthsAs given in this study (mouse).

    Source sentences

    Summary
    the number of mice with metastases to the lung in all three groups was practically identical
    1 context sentence
    Summary · context
    Female transgenic FVB mice transfected with the mammary erbB-2/neu oncogene were injected 0.1 ml 0.9% solution of sodium chloride (control), 1 meg Vilon peptide (Lys-Glu) or Epitalon peptide (Ala-Glu-Asp-Glu), s.c., 5 days in succession once a month, beginning from the age of 2 months.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In erbB-2/neu transgenic mice, the incidence of lung metastases was 2.6 times higher with Vilon than with epitalon (p < 0.05).

    In plain wordsIn mice, lung metastases were less frequent with epitalon than with Vilon.

    Peptide
    Epitalon
    Outcome
    DecreaseLung metastasis incidence versus Vilon
    Study

    mousen: not reported in source

    transgenic erbB-2/neu FVB mice with mammary carcinogenesis
    Comparator
    Vilon
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1 meg · subcutaneous · 5 days in succession once a month from age 2 monthsAs given in this study (mouse).

    Measurements

    Metastasis incidence ratio, Vilon vs Epitalon
    2.6 fold
    lung metastases

    Source sentences

    Summary
    their incidence in the Vilon group was 2.6 times higher than in Epitalon-treated animals (p < 0.05).
    1 context sentence
    Summary · context
    Female transgenic FVB mice transfected with the mammary erbB-2/neu oncogene were injected 0.1 ml 0.9% solution of sodium chloride (control), 1 meg Vilon peptide (Lys-Glu) or Epitalon peptide (Ala-Glu-Asp-Glu), s.c., 5 days in succession once a month, beginning from the age of 2 months.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In erbB-2/neu transgenic mice, the largest metastasis diameter was smallest in the epitalon group.

    In plain wordsIn mice, the largest metastases were smallest in the epitalon group.

    Peptide
    Epitalon
    Outcome
    DecreaseLargest diameter of metastasis
    Study

    mousen: not reported in source

    transgenic erbB-2/neu FVB mice with mammary carcinogenesis
    Comparator
    Saline control and Vilon
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1 meg · subcutaneous · 5 days in succession once a month from age 2 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Largest diameter of metastasis in the Epitalon group was the smallest, too.
    1 context sentence
    Summary · context
    Female transgenic FVB mice transfected with the mammary erbB-2/neu oncogene were injected 0.1 ml 0.9% solution of sodium chloride (control), 1 meg Vilon peptide (Lys-Glu) or Epitalon peptide (Ala-Glu-Asp-Glu), s.c., 5 days in succession once a month, beginning from the age of 2 months.
  9. 09AnimalAnimal study (in vivo)Safety outcome

    In transgenic mice, mammary tumor induction did not differ between Vilon and control groups until nine months of age.

    In plain wordsIn mice, mammary tumor development did not differ between Vilon and control groups until nine months.

    Peptide
    Vilon (KE)
    Outcome
    No significant changeMammary tumor induction through nine months
    Study

    mousen: not reported in source

    Female transgenic FVB erbB-2/neu mice
    Comparator
    Sodium chloride control
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1 meg · subcutaneousAs given in this study (mouse).

    Source sentences

    Summary
    The characteristics of mammary tumor induction in the control and experimental groups did not differ until the age of 9 months.
    1 context sentence
    Summary · context
    Female transgenic FVB mice transfected with the mammary erbB-2/neu oncogene were injected 0.1 ml 0.9% solution of sodium chloride (control), 1 meg Vilon peptide (Lys-Glu) or Epitalon peptide (Ala-Glu-Asp-Glu), s.c., 5 days in succession once a month, beginning from the age of 2 months.
  10. 10AnimalAnimal study (in vivo)Safety outcome

    In transgenic mice, one tumor per animal occurred in 4% with Vilon versus 7% in controls.

    In plain wordsIn mice, one tumor occurred in fewer Vilon-treated animals than controls.

    Peptide
    Vilon (KE)
    Outcome
    DecreaseOne tumor per animal
    Study

    mousen: not reported in source

    Female transgenic FVB erbB-2/neu mice
    Comparator
    Sodium chloride control
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1 meg · subcutaneousAs given in this study (mouse).

    Measurements

    One tumor per animal
    4%
    Vilon
    One tumor per animal
    7%
    control

    Source sentences

    Summary
    One tumor per animal was detected in 7% (control), 4% (Vilon) and 16% (Epitalon) (p < 0.05).
    1 context sentence
    Summary · context
    Female transgenic FVB mice transfected with the mammary erbB-2/neu oncogene were injected 0.1 ml 0.9% solution of sodium chloride (control), 1 meg Vilon peptide (Lys-Glu) or Epitalon peptide (Ala-Glu-Asp-Glu), s.c., 5 days in succession once a month, beginning from the age of 2 months.
  11. 11AnimalAnimal study (in vivo)Safety outcome

    In transgenic mice, two or more tumors occurred in 95% with Vilon versus 75% in controls.

    In plain wordsIn mice, multiple tumors occurred more often with Vilon than control.

    Peptide
    Vilon (KE)
    Outcome
    IncreaseTwo or more tumors per animal
    Study

    mousen: not reported in source

    Female transgenic FVB erbB-2/neu mice
    Comparator
    Sodium chloride control
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1 meg · subcutaneousAs given in this study (mouse).

    Measurements

    Two or more tumors
    95%
    Vilon
    Two or more tumors
    75%
    control

    Source sentences

    Summary
    Two or more tumors per animal were in 75%, 95% and 56%, respectively (p < 0.05).
    2 context sentences
    Summary · context
    One tumor per animal was detected in 7% (control), 4% (Vilon) and 16% (Epitalon) (p < 0.05).
    Summary · context
    Female transgenic FVB mice transfected with the mammary erbB-2/neu oncogene were injected 0.1 ml 0.9% solution of sodium chloride (control), 1 meg Vilon peptide (Lys-Glu) or Epitalon peptide (Ala-Glu-Asp-Glu), s.c., 5 days in succession once a month, beginning from the age of 2 months.
  12. 12AnimalAnimal study (in vivo)Safety outcome

    In transgenic mice, the number with lung metastases was practically identical in Vilon and control groups.

    In plain wordsIn mice, similar numbers developed lung metastases with Vilon and control.

    Peptide
    Vilon (KE)
    Outcome
    No significant changeMice with lung metastases
    Study

    mousen: not reported in source

    Female transgenic FVB erbB-2/neu mice
    Comparator
    Sodium chloride control
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1 meg · subcutaneousAs given in this study (mouse).

    Source sentences

    Summary
    Although the number of mice with metastases to the lung in all three groups was practically identical
    1 context sentence
    Summary · context
    Female transgenic FVB mice transfected with the mammary erbB-2/neu oncogene were injected 0.1 ml 0.9% solution of sodium chloride (control), 1 meg Vilon peptide (Lys-Glu) or Epitalon peptide (Ala-Glu-Asp-Glu), s.c., 5 days in succession once a month, beginning from the age of 2 months.
  13. 13AnimalAnimal study (in vivo)Safety outcome

    In transgenic mice, the number with lung metastases was practically identical in Vilon and Epitalon groups.

    In plain wordsIn mice, similar numbers developed lung metastases with Vilon and Epitalon.

    Peptide
    Vilon (KE)
    Outcome
    No significant changeMice with lung metastases
    Study

    mousen: not reported in source

    Female transgenic FVB erbB-2/neu mice
    Comparator
    Epitalon
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1 meg · subcutaneousAs given in this study (mouse).

    Source sentences

    Summary
    Although the number of mice with metastases to the lung in all three groups was practically identical
    1 context sentence
    Summary · context
    Female transgenic FVB mice transfected with the mammary erbB-2/neu oncogene were injected 0.1 ml 0.9% solution of sodium chloride (control), 1 meg Vilon peptide (Lys-Glu) or Epitalon peptide (Ala-Glu-Asp-Glu), s.c., 5 days in succession once a month, beginning from the age of 2 months.
  14. 14AnimalAnimal study (in vivo)Safety outcome

    In transgenic mice, lung metastasis incidence with Vilon was 2.6 times that with Epitalon.

    In plain wordsIn mice, lung metastasis incidence was higher with Vilon than Epitalon.

    Peptide
    Vilon (KE)
    Outcome
    IncreaseLung metastasis incidence
    Study

    mousen: not reported in source

    Female transgenic FVB erbB-2/neu mice
    Comparator
    Epitalon
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1 meg · subcutaneousAs given in this study (mouse).

    Measurements

    Relative metastasis incidence
    2.6 times
    Vilon versus Epitalon

    Source sentences

    Summary
    Although the number of mice with metastases to the lung in all three groups was practically identical, their incidence in the Vilon group was 2.6 times higher than in Epitalon-treated animals (p < 0.05).
    1 context sentence
    Summary · context
    Female transgenic FVB mice transfected with the mammary erbB-2/neu oncogene were injected 0.1 ml 0.9% solution of sodium chloride (control), 1 meg Vilon peptide (Lys-Glu) or Epitalon peptide (Ala-Glu-Asp-Glu), s.c., 5 days in succession once a month, beginning from the age of 2 months.
  15. 15AnimalAnimal study (in vivo)Safety outcome

    In transgenic mice, mammary tumor induction did not differ between Vilon and Epitalon groups until nine months of age.

    In plain wordsIn mice, mammary tumor development did not differ between Vilon and Epitalon groups until nine months.

    Peptide
    Vilon (KE)
    Outcome
    No significant changeMammary tumor induction through nine months
    Study

    mousen: not reported in source

    Female transgenic FVB erbB-2/neu mice
    Comparator
    Epitalon
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1 meg · subcutaneousAs given in this study (mouse).

    Source sentences

    Summary
    The characteristics of mammary tumor induction in the control and experimental groups did not differ until the age of 9 months.
    1 context sentence
    Summary · context
    Female transgenic FVB mice transfected with the mammary erbB-2/neu oncogene were injected 0.1 ml 0.9% solution of sodium chloride (control), 1 meg Vilon peptide (Lys-Glu) or Epitalon peptide (Ala-Glu-Asp-Glu), s.c., 5 days in succession once a month, beginning from the age of 2 months.
  16. 16AnimalAnimal study (in vivo)Safety outcome

    In transgenic mice, one tumor per animal occurred in 4% with Vilon versus 16% with Epitalon.

    In plain wordsIn mice, one tumor occurred in fewer Vilon-treated animals than Epitalon-treated animals.

    Peptide
    Vilon (KE)
    Outcome
    DecreaseOne tumor per animal
    Study

    mousen: not reported in source

    Female transgenic FVB erbB-2/neu mice
    Comparator
    Epitalon
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1 meg · subcutaneousAs given in this study (mouse).

    Measurements

    One tumor per animal
    4%
    Vilon
    One tumor per animal
    16%
    Epitalon

    Source sentences

    Summary
    One tumor per animal was detected in 7% (control), 4% (Vilon) and 16% (Epitalon) (p < 0.05).
    1 context sentence
    Summary · context
    Female transgenic FVB mice transfected with the mammary erbB-2/neu oncogene were injected 0.1 ml 0.9% solution of sodium chloride (control), 1 meg Vilon peptide (Lys-Glu) or Epitalon peptide (Ala-Glu-Asp-Glu), s.c., 5 days in succession once a month, beginning from the age of 2 months.
  17. 17AnimalAnimal study (in vivo)Safety outcome

    In transgenic mice, two or more tumors occurred in 95% with Vilon versus 56% with Epitalon.

    In plain wordsIn mice, multiple tumors occurred more often with Vilon than Epitalon.

    Peptide
    Vilon (KE)
    Outcome
    IncreaseTwo or more tumors per animal
    Study

    mousen: not reported in source

    Female transgenic FVB erbB-2/neu mice
    Comparator
    Epitalon
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1 meg · subcutaneousAs given in this study (mouse).

    Measurements

    Two or more tumors
    95%
    Vilon
    Two or more tumors
    56%
    Epitalon

    Source sentences

    Summary
    Two or more tumors per animal were in 75%, 95% and 56%, respectively (p < 0.05).
    2 context sentences
    Summary · context
    One tumor per animal was detected in 7% (control), 4% (Vilon) and 16% (Epitalon) (p < 0.05).
    Summary · context
    Female transgenic FVB mice transfected with the mammary erbB-2/neu oncogene were injected 0.1 ml 0.9% solution of sodium chloride (control), 1 meg Vilon peptide (Lys-Glu) or Epitalon peptide (Ala-Glu-Asp-Glu), s.c., 5 days in succession once a month, beginning from the age of 2 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 10Current

    28 Oct 2026, 02:02 UTC

    The same notice was added 7 times, first on 21 Oct 2026, 17:05 UTC. The status did not change between them.

    Study results updated

  2. Version 3

    21 Oct 2026, 16:35 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    12 Oct 2026, 17:28 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.